Trexquant Investment LP Krystal Biotech, Inc. Transaction History

Trexquant Investment LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$108.01 - $179.35 $1.44 Million - $2.38 Million	13,293 New	13,293 $2.37 Million
Q3 2023 Nov 13, 2023	BUY	$108.51 - $130.22 $71,291 - $85,554	657 Added 8.81%	8,113 $941,000
Q2 2023 Aug 11, 2023	BUY	$78.48 - $130.32 $585,146 - $971,665	7,456 New	7,456 $875,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.